New Pharmaceuticals market report from TechNavio: "Global Ovarian Cancer Market 2014-2018"

Boston, MA -- (ReleaseWire) -- 07/08/2014 --Ovarian cancer is a condition where a malignancy forms in the ovarian tissue and is caused by uncontrollable cell growth. It is one of the major gynaecological cancers worldwide and a leading cause of death. Ovarian cancer is difficult to diagnose in the initial stages because the symptoms are similar to that of gastric disorders like bloating, abdominal discomfort, difficulty in eating in the early stage and nausea, vomiting, constipation and diarrhoea in the later stages. It is often diagnosed in advanced stages when the metastasis has set in because the diagnostic techniques are not well-developed. Ovarian cancer can be treated by using chemotherapy, targeted therapy, and surgery. Although the market has a limited number of drugs for the treatment of ovarian cancer currently, a strong product pipeline is in development for the forecast period.

View Full Report Details and Table of Contents

TechNavio's analysts forecast the Global Ovarian Cancer market will grow at a CAGR of 13.85 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Ovarian Cancer market for the period 2013-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of ovarian cancer that are available in the market.

TechNavio's report, the Global Ovarian Cancer Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Ovarian Cancer market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

- Americas
- EMEA
- APAC

Key Vendors

- Bristol Myers Squibb Company
- Eli Lilly and Company
- GlaxoSmithKline plc
- Janssen Pharmaceuticals Inc.
- F. Hoffman-La Roche Ltd

Other Prominent Vendors

- Aprea AB
- Aetera Zenteris Inc.
- Amgen Inc.
- Astra Zeneca plc
- Bionumerik Pharmaceuticals Inc.
- Boehringer Ingelheim GmbH
- Genentech Inc.
- MEI Pharmaceuticals Inc.
- Nektar Therapeutics
- NeoPharm Inc.
- Novogen Inc.
- Oasmia Pharmaceuticals AB
- Synta Pharmaceuticals Corp.

Key Market Driver

- Promising Drug Pipeline.
- For a full, detailed list, view our report.

Key Market Challenge

- Lack of Accurate Diagnosis of Ovarian Cancer.
- For a full, detailed list, view our report.

Key Market Trend

- Increase in the Funding Activities.
- For a full, detailed list, view our report.

Key Questions Answered in this Report

- What will the market size be in 2018 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Companies Mentioned in this Report: Bristol Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Janssen Pharmaceuticals Inc., F. Hoffman-La Roche Ltd, Aprea AB, Aetera Zenteris Inc., Amgen Inc., Astra Zeneca plc, Bionumerik Pharmaceuticals Inc., Boehringer Ingelheim GmbH, Genentech Inc., MEI Pharmaceuticals Inc., Nektar Therapeutics, NeoPharm Inc., Novogen Inc., Oasmia Pharmaceuticals AB, Synta Pharmaceuticals Corp.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014
- Ovarian Cancer Global Clinical Trials Review, H2, 2013
- Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies
- Epithelial Ovarian Cancer - Pipeline Review, H1 2014
- Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies
- Metastatic Ovarian Cancer - Pipeline Review, H1 2014
- Ovarian Cancer - Pipeline Review, H1 2013
- Epithelial Ovarian Cancer - Pipeline Review, H2 2013
- Metastatic Ovarian Cancer - Pipeline Review, H1 2013
- Cancer Pain Global Clinical Trials Review, H1, 2013